AliveCor brings world’s only six-lead, FDA-cleared personal ECG device to India

AliveCor’s entry into India comes at an opportune time when the public is cautioned to stay at home and the condition of most patients suffering from heart abnormalities has been worsening

New Delhi: In India, CVDs have become the leading cause of mortality. Owing to mobility restrictions due to the COVID-19 pandemic followed by infection scare at hospitals hampering regular check-ups, cardiovascular patients in India are facing acute health crisis which contribute to adverse clinical events and mortality.
In this backdrop, AliveCor, the global leader in US FDA-cleared personal electrocardiogram (ECG) technology, has announced its entry in the Indian market with the revolutionary launch of the most clinically-validated personal ECG device, KardiaMobile 6L. Owing to the accessibility challenges to quality healthcare in the country and COVID related infection fears, the portable and technology-enabled ECG device will help deliver affordable and convenient heart care to over 260 million heart patients and those at risk, without visiting a hospital.
KardiaMobile 6L is the only personal ECG device in the world that can detect the three most common arrhythmias or irregular heartbeat—atrial fibrillation (AFib), bradycardia, and tachycardia, which require regular monitoring and a healthy lifestyle. AliveCor’s innovative technology gives patients the ability to record a medical-grade ECG in just 30 seconds, with no hospital visits and complete peace of mind. The device is small enough to fit in a pocket, allowing users to check in on their heart anytime, anywhere right from their smartphone. In a country like India where over 70% of the population owns a smartphone, this technology comes as a big boost to make heart care accessible, affordable and convenient.
Across the world, cardiovascular disease (CVD) is the leading cause of mortality. According to The Lancet report, an estimated 54.5 million people are affected by CVD in India, leading to one in four deaths. Reports also suggest that arrhythmias, like AFib, affect an estimated 10 million people in India and are leading indicators of heart disease and stroke.
AliveCor’s entry into India comes at an opportune time when the public is cautioned to stay at home and the condition of most patients suffering from heart abnormalities has been worsening. While infection scare at hospitals is hampering regular check-ups, KardiaMobile 6L gives consumers the ability to keep track of their heart health from the comfort of home. The pocket-sized, portable device enables clinicians to manage patients remotely. Considering the ongoing health crisis, use of KardiaMobile 6L reassures optimal clinical control and caters to the need for efficient tools for safe out-of-hospital management. For patients with pre-existing conditions or those who feel a symptom, it provides convenience to track heart health on-the-go without hospital visits.
Priya Abani, Chief Executive Officer, AliveCor mentioned, “With hundreds of millions at risk for heart disease across the globe, accessible heart care has never been more important. AliveCor’s expansion into India is pivotal to our mission of providing remote, medical-grade heart care to those who need it most. We are committed to innovating digital health services in India by offering patients the ability to take control of their own heart health from the comfort of home.”
As digital health emerges as a key objective for India where healthcare accessibility is a concern, mobile healthcare through a device like KardiaMobile 6L bears utmost value. AliveCor’s Kardia devices have catered to nearly 1 million users, across 37 countries, and recorded more than 80 million ECGs till date. Early detection of arrhythmias is critical, and through the launch of KardiaMobile 6L, AliveCor puts the power of early detection directly into the hands of patients in India.
AliveCor’s KardiaMobile 6L is priced at INR 14000 and KardiaMobile is priced at INR 8500. They are available for purchase at